No Data
No Data
No Data
No Data
No Data
友芝友生物-B:2023年度報告
Futu NewsApr 26 05:26 ET · Announcements
YZYBIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Futu NewsMar 28 08:14 ET · Announcements
Tomoshibayu Bio-B (02496.HK): Phase III clinical trial of the bispecific antibody M701 malignant ascites completed the first patient enrollment
On March 27, Ge Longhui | Youzhiyou Bio-B (02496.HK) announced that M701, an investigational bispecific antibody (“BsAb”) that targets both epithelial cell adhesion molecule (“epCAM”) and differentiation cluster 3 (“CD3”) independently developed by the company, recently completed the first case of patients enrolled in a critical phase III registered clinical trial (“malignant ascites study”). The purpose of the malignant ascites study was to evaluate the efficacy and safety of peritoneal perfusion M701 compared with abdominal puncture drainage in patients with malignant ascites caused by advanced solid epithelial tumors. If successful, malignant ascites research will be used to support
Gelonghui FinanceMar 27 09:16 ET
Tomoshibayu Bio-B (02496): Phase II clinical trial of the bispecific antibody M701 malignant pleural effusion completed the first patient enrollment
Tomoshibayu Bio-B (02496) announced that the company's self-developed epithelial cell adhesion molecule (epCAM)...
Zhitong FinanceMar 26 11:19 ET
Tomoshiba Biological-B (02496.HK) plans to hold a board meeting on March 28 to approve annual results
Gelonghui March 15 | YouzhiYouBio-B (02496.HK) announced that the board of directors announced that a board meeting will be held on March 28, 2024 (Thursday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to deal with other matters.
Gelonghui FinanceMar 15 04:50 ET
Double Anti-Aura Can't Save YouZhiyou Biotech - B (02496): The stock price dropped after half a year of listing, and the cornerstone duvet cover
As of February 20 this year, the company's stock price was only HK$8.74, down 45.38% from the issue price. This is clearly far below the subscription price of Cornerstone Investors during the IPO stage. Today, it is only one month until the listing ban is lifted on March 24 this year.
Zhitong FinanceFeb 20 04:30 ET
No Data
No Data